BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies with a 5 year Revenue Growth Rate of 608%
June 12 2014 - 4:01PM
Marketwired
BioSyent Named to the PROFIT 500 Ranking of Canada's
Fastest-Growing Companies with a 5 year Revenue Growth Rate of 608%
TORONTO, ONTARIO--(Marketwired - Jun 12, 2014) - BioSyent Inc.
("BioSyent") (TSX-VENTURE:RX) is pleased to announce that Canadian
Business and PROFIT has ranked BioSyent as one of Canada's
Fastest-Growing Companies in the just released 2014 rankings.
Published in the July issue of Canadian Business and online at
PROFITguide.com, the PROFIT 500 ranks Canadian businesses by their
revenue growth over five years. Based upon a five year revenue
(2008-2013) growth rate of 608%, BioSyent ranked 104 on the PROFIT
500 list. This is the second consecutive year that BioSyent has
been named to the Profit 500 list and marks a significant increase
in 5 year growth rate, from 355% on last year's list to 608% on
this year's list.
For a direct market quote (15 minutes delay) for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
About BioSyent Inc.
Listed on the Toronto Venture Exchange under the trading symbol
"RX", BioSyent is a profitable growth oriented specialty
pharmaceutical company which searches the globe to in-license or
acquire innovative pharmaceutical products that have been
successfully developed, are safe and effective, and have a proven
track record of improving the lives of patients and supporting the
healthcare professionals that treat them.
Once a product of interest has been found, BioSyent then
acquires the exclusive rights to the product and manages it through
the Canadian governmental regulatory approval process. Once
approved, BioSyent markets the product throughout Canada.
At the date of this press release the Company had 13,801,195
shares issued and outstanding.
This press release may contain information or statements that
are forward-looking. The contents herein represent our judgment, as
at the release date, and are subject to risks and uncertainties
that may cause actual results or outcomes to be materially
different from the forward-looking information or statements.
Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future
revenue, operations, profitability and obtaining regulatory
approvals.
The TSX Venture
Exchange assumes no responsibility for the accuracy of this release
and neither approves nor disapproves of the same.
BioSyent Inc.Mr. Rene C. GoehrumPresident and CEO(905)
206-0013investors@biosyent.comwww.biosyent.com
Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2023 to Jul 2024